Efficacy of paclitaxel/dexamethasone intra-tumoral delivery in treating orthotopic mouse breast cancer

Hen Popilski, Esther Abtew, Steven Schwendeman, Abraham Domb, David Stepensky

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


The effect of topical co-administration of promoter drugs with paclitaxel to increase anti-tumor effects of paclitaxel was investigated. Mice with orthotopic 4T1-Luc breast cancer received single intra-tumoral injection of a polymeric formulation with paclitaxel and a specific promoter drug. Several promoter drugs were evaluated, including: dexamethasone, losartan, nicotinamide, Azone, and oleic acid. Dexamethasone exhibited the highest effect on paclitaxel anti-tumor activity, in a dose-dependent fashion. However, this effect was accompanied by systemic effects of dexamethasone, and inability to prevent tumor metastasis to the lungs. Topical co-administration of promoter drugs with anti-cancer agents can enhance their anti-tumor effects. Further investigations are needed to identify the most efficient combinations of promoter and anti-cancer drugs, and their suitability for the clinical management of the breast cancer disease.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalJournal of Controlled Release
StatePublished - 10 Jun 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2018 Elsevier B.V.


  • Dexamethasone
  • Intra-tumoral implant
  • Local anti-cancer treatment
  • Orthotopic model of breast cancer
  • Paclitaxel
  • Promoter drugs


Dive into the research topics of 'Efficacy of paclitaxel/dexamethasone intra-tumoral delivery in treating orthotopic mouse breast cancer'. Together they form a unique fingerprint.

Cite this